Samjin Pharmaceuticals Co., Ltd. (005500.KS)
KRW 18280.0
(-0.33%)
KRW 18280.0
(-0.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 36.63 Billion KRW | 6.77% |
| 2022 | 33 Billion KRW | -18.74% |
| 2021 | 41.27 Billion KRW | 5.81% |
| 2020 | 39.36 Billion KRW | 37.17% |
| 2019 | 27.57 Billion KRW | -56.88% |
| 2018 | 66.34 Billion KRW | 24.52% |
| 2017 | 53.25 Billion KRW | 9.18% |
| 2016 | 46.29 Billion KRW | 14.65% |
| 2015 | 42.04 Billion KRW | 12.59% |
| 2014 | 37.6 Billion KRW | 5.37% |
| 2013 | 35.9 Billion KRW | 71.77% |
| 2012 | 20.87 Billion KRW | -24.07% |
| 2011 | 27.48 Billion KRW | 4.96% |
| 2010 | 26.27 Billion KRW | 72.08% |
| 2009 | 15.26 Billion KRW | 2.93% |
| 2008 | 14.84 Billion KRW | -11.56% |
| 2007 | 16.84 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 10.34 Billion KRW | -8.32% |
| 2024 Q2 | 11.2 Billion KRW | 234.63% |
| 2023 Q4 | 11.62 Billion KRW | -60.46% |
| 2023 FY | - KRW | 6.77% |
| 2023 Q1 | 28.03 Billion KRW | 164.0% |
| 2023 Q2 | 27.43 Billion KRW | -2.13% |
| 2023 Q3 | 29.39 Billion KRW | 7.14% |
| 2022 FY | - KRW | -18.74% |
| 2022 Q3 | 8.74 Billion KRW | 37.28% |
| 2022 Q4 | 10.61 Billion KRW | 21.41% |
| 2022 Q1 | 7.33 Billion KRW | 505.99% |
| 2022 Q2 | 6.37 Billion KRW | -13.19% |
| 2021 Q2 | 11.87 Billion KRW | 29.54% |
| 2021 Q4 | -1.8 Billion KRW | -108.11% |
| 2021 Q3 | 22.29 Billion KRW | 87.79% |
| 2021 FY | - KRW | 5.81% |
| 2021 Q1 | 9.16 Billion KRW | 42.76% |
| 2020 FY | - KRW | 37.17% |
| 2020 Q1 | 12.43 Billion KRW | 142.83% |
| 2020 Q3 | 8.7 Billion KRW | -24.54% |
| 2020 Q4 | 6.41 Billion KRW | -26.24% |
| 2020 Q2 | 11.53 Billion KRW | -7.24% |
| 2019 Q1 | 16.56 Billion KRW | -6.97% |
| 2019 Q2 | 15.38 Billion KRW | -7.09% |
| 2019 Q4 | 5.12 Billion KRW | -61.86% |
| 2019 FY | - KRW | -56.88% |
| 2019 Q3 | 13.42 Billion KRW | -12.74% |
| 2018 Q4 | 17.8 Billion KRW | 8.91% |
| 2018 FY | - KRW | 24.52% |
| 2018 Q3 | 16.34 Billion KRW | -1.97% |
| 2018 Q2 | 16.67 Billion KRW | 6.42% |
| 2018 Q1 | 15.66 Billion KRW | 44.68% |
| 2017 Q1 | 12.91 Billion KRW | 22.88% |
| 2017 Q2 | 14.11 Billion KRW | 9.35% |
| 2017 Q3 | 15.57 Billion KRW | 10.29% |
| 2017 FY | - KRW | 9.18% |
| 2017 Q4 | 10.82 Billion KRW | -30.46% |
| 2016 Q4 | 10.5 Billion KRW | -23.12% |
| 2016 Q1 | 12.27 Billion KRW | 50.36% |
| 2016 FY | - KRW | 14.65% |
| 2016 Q2 | 12.54 Billion KRW | 2.18% |
| 2016 Q3 | 13.66 Billion KRW | 8.99% |
| 2015 Q4 | 8.16 Billion KRW | -31.23% |
| 2015 Q2 | 11.72 Billion KRW | 7.97% |
| 2015 FY | - KRW | 12.59% |
| 2015 Q3 | 11.86 Billion KRW | 1.25% |
| 2015 Q1 | 10.85 Billion KRW | 49.2% |
| 2014 Q2 | 10.09 Billion KRW | -5.59% |
| 2014 Q1 | 10.69 Billion KRW | 46.6% |
| 2014 FY | - KRW | 5.37% |
| 2014 Q4 | 7.27 Billion KRW | -24.54% |
| 2014 Q3 | 9.64 Billion KRW | -4.46% |
| 2013 Q3 | 9.17 Billion KRW | 5.12% |
| 2013 FY | - KRW | 71.77% |
| 2013 Q2 | 8.72 Billion KRW | -15.77% |
| 2013 Q1 | 10.36 Billion KRW | 97.99% |
| 2013 Q4 | 7.29 Billion KRW | -20.49% |
| 2012 Q1 | 4.39 Billion KRW | 1528.29% |
| 2012 Q2 | 4.67 Billion KRW | 6.53% |
| 2012 Q3 | 6.49 Billion KRW | 38.81% |
| 2012 Q4 | 5.23 Billion KRW | -19.4% |
| 2012 FY | - KRW | -24.07% |
| 2011 Q4 | -307.38 Million KRW | -105.77% |
| 2011 Q1 | 7.77 Billion KRW | 32.24% |
| 2011 Q2 | 14.54 Billion KRW | 87.16% |
| 2011 FY | - KRW | 4.96% |
| 2011 Q3 | 5.32 Billion KRW | -63.37% |
| 2010 FY | - KRW | 72.08% |
| 2010 Q2 | 5.64 Billion KRW | -3.62% |
| 2010 Q3 | 8.88 Billion KRW | 57.28% |
| 2010 Q1 | 5.86 Billion KRW | 329.88% |
| 2010 Q4 | 5.87 Billion KRW | -33.86% |
| 2009 Q3 | 4.22 Billion KRW | -2.1% |
| 2009 Q4 | 1.36 Billion KRW | -67.7% |
| 2009 Q1 | 5.37 Billion KRW | 126.51% |
| 2009 FY | - KRW | 2.93% |
| 2009 Q2 | 4.31 Billion KRW | -19.71% |
| 2008 Q3 | 3 Billion KRW | -28.91% |
| 2008 Q4 | 2.37 Billion KRW | -21.01% |
| 2008 FY | - KRW | -11.56% |
| 2008 Q1 | 5.23 Billion KRW | 5.24% |
| 2008 Q2 | 4.22 Billion KRW | -19.38% |
| 2007 Q1 | 4.76 Billion KRW | 0.0% |
| 2007 Q3 | 3 Billion KRW | -25.18% |
| 2007 Q2 | 4.02 Billion KRW | -15.63% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | 4.97 Billion KRW | 65.42% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -654.054% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 74.085% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 157.209% |
| HANDOK Inc. | 35.06 Billion KRW | -4.471% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 3634.183% |
| Yuhan Corporation | 127.43 Billion KRW | 71.252% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 2.363% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 268.919% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 88.67% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -634.11% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -142.32% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -970.878% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -709.351% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -3.235% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -654.054% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 298.326% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -458.881% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 174.321% |
| JW Holdings Corporation | 187.88 Billion KRW | 80.502% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 171.512% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 87.084% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 58.939% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 198.834% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -177.332% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -209.73% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -96.38% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -654.054% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 33.359% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 77.786% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 58.939% |
| Yuhan Corporation | 127.43 Billion KRW | 71.252% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -9.435% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -378.892% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 52.44% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 58.939% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 48.242% |
| CKD Bio Corp. | -1.63 Billion KRW | 2346.902% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 26.426% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -12.509% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 0.478% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 198.834% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 41.182% |
| Boryung Corporation | 114.28 Billion KRW | 67.946% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 219.845% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -142.32% |
| JW Lifescience Corporation | 50.82 Billion KRW | 27.926% |